Chapter 1. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

 2.3.1. Impact during 2023 - 2030

  2.3.2. Impact on Supply – Demand

Chapter 3. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET –  Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET -  Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunitie

Chapter 6. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – By Drug Type

• 1. Synthetic (sDMARD)
• Conventional synthetic (csDMARDs)

• Methotrexate
• Sulfasalazine
• Leflunomide
• Hydroxychloroquine
• Gold Salts

• Targeted synthetic DMARDs (tsDMARDs)
• Biological DMARDs (bDMARD)

• Original DMARDs (boDMARDs)
• Biosimilar DMARDs (bsDMARDs)

• Primary
• Secondary
• Tertiary
• Others

Chapter 7. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – By Route Of Administration

7.1. Oral

7.2. Parenteral

7.3. Others

Chapter 8. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – By  Indication

8.1. Rheumatoid Arthritis

8.2. Ankylosing Spondylitis

8.3. Psoriatic Arthritis

8.4. Systemic Lupus Erythematosus

8.5. Others

Chapter 9. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – By  Distribution Channel

9.1. Hospital Pharmacy

9.2. Retail Pharmacy

9.3. Online Pharmacy

Chapter 10. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – By Region

10.1. North America

10.2. Europe

10.3. Asia - Pacific

10.4. Latin America

10.5. The Middle East

10.6. Africa

Chapter 11. DMARDS(DISEASE-MODIFYING ANTIRHEUMATIC DRUGS) MARKET – By Companies

11.1. Company 1

11.2. Company 2

11.3. Company 3

11.4. Company 4

11.5. Company 5

11.6. Company 6

11.7. Company 7

11.8. Company 8

11.9. Company 9

11.10. Company 10

Download Sample